Conference
279 Study Design of a Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Over BAT in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (REACH-3)
Authors
Zeiser R; Ram R; Foley SR; Yeshurun M; Locatelli F; Artz A; Gadbaw B; Atienza E; Hollaender N; Delaite P
Volume
24
Publisher
Elsevier
Publication Date
March 1, 2018
DOI
10.1016/j.bbmt.2017.12.176
Conference proceedings
Transplantation and Cellular Therapy
Issue
3
ISSN
2666-6367